Advanced Solid Tumors Clinical Trial
— BM201-1001Official title:
The Study to Evaluate the Safety, PK, and Preliminary Efficacy of BM201 Injection Combined With Radiotherapy in Patients With Unresectable Locally Advanced or Metastatic Solid Tumors That Failed Standard Therapy
This is a non-randomized,open-label,controlled multi-center Phase Ⅰ study to evaluate tolerability, pharmacokinetics, and preliminary efficacy of BM201 injection in combination with radiotherapy in patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors who have failed standard therapy or are unable to receive standard treatment.
Status | Recruiting |
Enrollment | 36 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Unresectable advanced or metastatic solid tumors, either refractory to standard therapy or ineligible for standard treatment. 2. ECOG performance status score of 0-2 point; 3. Expected survival of =3 months. 4. At least one measurable lesion by irRECIST criteria, and eligible for intratumoral injection. 5. Prior anti-tumor treatments should be paused for at least 4 weeks before trial initiation,with toxicity related to anti-cancer treatment recovered to =Grade 1. 6. Adequate organ and bone marrow function Exclusion Criteria: 1. Patients with active brain metastasis and/or leptomeningeal carcinomatosis,exempt for asymptomatic brain metastases or stable metastatic lesions for a minimum of 4 weeks. 2. Allergic: History of hypersensitivity to active ingredients or any other components of the study medication; cumulative two or more allergies to contrast agents, other drugs, or food. 3. Active hepatitis B or positive antibodies for hepatitis C, human immunodeficiency virus (HIV), or syphilis. 4. Severe cardiac or cerebrovascular conditions, uncontrolled diabetes, hypertension not well-managed medically (systolic >140 mmHg and/or diastolic >90 mmHg), serious infections (active within 14 days before first drug administration/radiotherapy), active GI ulcers, and immune dysfunction. 5. Presence of other active malignancies or history thereof, except for previously managed non-invasive skin basal or squamous cell carcinomas with a 5-year recurrence-free interval, cervical carcinoma in situ, and ductal carcinoma in situ of the breast. 6. Uncontrolled third-space effusions such as pericardial, abdominal, or pleural within 2 weeks before the initial treatment. 7. Administration of corticosteroids within the preceding 2 weeks before initial treatment. 8. Receipt of vaccination within 2 weeks prior to initial therapy. 9. Participation in clinical trial involving drugs or biologics within 4 weeks before the initial treatment. 10. History of major surgery within 3 months prior to initial treatment or scheduled major surgery during the clinical trial period. 11. Prior blood donation or major hemorrhage (>450 mL) within 3 months before initial therapy, or intention to donate blood/blood components during or within 3 months after the trial. 12. Patients with difficult venous access or intolerance to venipuncture, and those unable to tolerate intratumoral injection. 13. Pregnant (positive pregnancy test) and lactating females. 14. Subjects planning pregnancy or gamete donation within 3 months post-consent and unwilling to practice effective contraception. 15. Patients deemed ineligible for enrollment by the investigator. |
Country | Name | City | State |
---|---|---|---|
China | Nanjing Drum Towel Hospital /The Affiliated Hospital of Nanjing University Medical School | Nanjing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
InnoBM Pharmaceuticals Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | DLT and MTD | Dose limiting toxicity and maximum tolerated dose | Up to 14 days after the initial treatment | |
Primary | Pharmacokinetic (PK) parameters | Maximum plasma concentration(Cmax) of the drug after administration | From pre-dose to 96 hrs post-dose | |
Primary | Number of patients with adverse events (AEs) | Number of patients with treatment-related adverse events (AEs) | From the first treatment to 42 days after the last treatment. | |
Secondary | ORR | Objective Response Rate | Up to 42 days after the last treatment | |
Secondary | Peripheral blood cytokine profiling in study participants. | To investigate the change of peripheral blood cytokine level in subjects after the treatment. | From pre-dose/pre-radiation to 4 hrs post-dose/post-radiation. | |
Secondary | The variation in peripheral blood tumor biomarker concentrations. | The variation of concentrations of AFP,NSE,CEA ; | Up to 42 days after the last treatment | |
Secondary | Other exploring outcomes | The variation of tumor tissue biomarker expression levels | Up to 14 days after the initial treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04972981 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT05086822 -
A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03260322 -
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT06040541 -
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05862831 -
Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03641794 -
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT03665129 -
IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10579 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05914116 -
A Study of DB-1311 in Advanced/Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01693562 -
A Phase 1/2 Study to Evaluate MEDI4736
|
Phase 1/Phase 2 | |
Recruiting |
NCT04387916 -
A Study of KC1036 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04095273 -
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
|
Phase 1 | |
Not yet recruiting |
NCT03692520 -
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02997176 -
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
|
Phase 1 | |
Recruiting |
NCT04446260 -
A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02253992 -
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06076291 -
An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03545971 -
A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.
|
Phase 1 |